Retinal Sensitivity in BRVO After Anti-VEGF Therapy
Branch Retinal Vein OcclusionThe efficacy of anti-vascular endothelial growth factor (VEGF) therapy for branch retinal vein occlusion (BRVO) is shown, but its effect on retinal sensitivity is not fully investigated. The purpose of this study is to compare the changes in retinal sensitivity after ranibizumab therapy or combination therapy of ranibizumab and laser photocoagulation in eyes with BRVO.
Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular...
Age-related Macular DegenerationDiabetic Retinopathy3 moreThe purpose of this study is to determine whether phase variance optical coherence tomography (PV-OCT), a software-based optical coherence tomography(OCT) image processing technology, can be used to generate angiographic images of the retinochoroidal vasculature that are comparable to those produced by fluorescein angiography (FA), the current gold standard diagnostic test.
Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO
Central Retinal Vein OcclusionRecent studies have shown that intravitreal injection of anti-VEGF agent, Lucentis (Ranibizumab) is effective for macular edema associated with central retinal vein occlusion (CRVO). However, there is little information on whether there are any predictive factors of treatment outcome after this treatment. We plan to perform comprehensive functional and imaging tests to determine significant predictive factors.
Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein...
Retinal Vein OcclusionThe primary objective is to demonstrate the non-inferiority of bevacizumab in the treatment of patients with macular edema secondary to a retinal vein occlusion (branch or central) as determined by the change in best-corrected visual acuity in the study eye from baseline to month 6.
Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal...
Branch Retinal Vein Occlusion With Macular EdemaThe purpose of this study is to evaluate the efficacy and safety of the treat-and-extend regimen extending to 4 months by intervals of 4 weeks using intravitreal aflivercept injection for treatment of macular edema secondary to BRVO.
Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion
Retinal Vein OcclusionTreatment2 moreRetinal vein occlusion (RVO) may lead to series of complications including retinal ischemia, macular edema (ME) and induce vision impairment. Intravitreal injection of Ranibizumab (0.5mg) has been proved to be a safe and effective method for the treatment of RVO-ME. In this study, different treatment regimens of Ranibizumab is applied and the effects is observed at 1-6 months to explore the best regimen for RVO. After 6 months, anti-VEGF therapy and/or laser photocoagulation is used to explore whether laser photocoagulation can maintain the therapeutic effect of Ranibizumab or reduce the injection number.
Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion
Branch Retinal Vein OcclusionThis randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.
601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
Central Retinal Vein OcclusionTo evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to CRVO
Near-Infrared Light Photobiomodulation Treatment for Retinal Vein Occlusion Macular Oedema
Macula EdemaRetinal Vein OcclusionThis pilot study aims to establish that treatment with near infrared light (NIR) reduces cystic macular oedema in patients with a retinal vein occlusion.
Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG
Ischaemic Central Retinal Vein OcclusionNeovascular GlaucomaA prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG Study